secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lipocine Inc. (LPCN)
CIK:        0001535955
Form:       8-K
Filed at:   2026-09-14T10:15:26+00:00
Accession:  0001493152-26-042466
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipocine initiates BLOOM Phase 3 of LPCN 1154 for postpartum depression
-----------------------------------------------------------------------

- BLOOM to enroll ~120 patients with severe PPD; first dosing expected early Q4 2026.
- Prior Phase 3 missed primary endpoint; post hoc analysis excluded one site with ~40% undetectable drug.
- No treatment-related severe/serious AEs or excessive sedation in prior Phase 3.
- Company has $23.3M cash (6/30/26); expects ~$1M/month cash use during study.
- Study incorporates FDA feedback and strengthened site quality controls.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1535955/000149315226042466/0001493152-26-042466-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1535955/000149315226042466/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-042466

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer